This is the authors' abstract. We don't add key points for this paper.
Introduction . An important characteristic of therapy with modified T-cells expressing the chimeric antigen receptor (CAR) is the duration of CAR T-cell persistence in the patient’s body. Prolonged re-stimulation of CAR T-cell product in vitro with further analysis of its subpopulation composition and cytotoxic activity is one of the approaches to model cell behavior in patients. Aim: to study the immunophenotype, exhaustion and functional characteristics of anti-CD19 CAR T-cell products derived from healthy donors and patients with B-cell acute lymphoblastic leukemia (B-ALL) at prolonged re-stimulation conditions in vitro. Materials and methods. Anti-CD19 CAR T-cell products were generated from 5 healthy donors and 3 patients with B-ALL. The immunophenotype of the obtained cell products was studied under conditions of repeated antigenic re-stimulation in vitro using the target cell line NALM6 carrying the CD19 antigen over 7-10 days. At each experimental timepoint, the following parameters were assessed: proliferative and cytotoxic activity, expression of exhaustion markers, and changes in the subpopulation composition of CAR T-memory cells (immunophenotype). Results. Anti-CD19 CAR T-cells had significant cytotoxic activity regardless of the lymphocyte source (healthy donors/patients). During prolonged antigenic re-stimulation of all products, a decrease in the proportion of naive (TN) and effector (TE) CAR T-cells, and an increase in the proportion of central (TCM) and effector memory (TEM) cells was observed. CAR T-cells showed increased expression of exhaustion markers (PD1, TIM3) irrespective of the origin of the cell and E:T ratio. Conclusion. Analysis of cytotoxic activity and immunophenotypic composition of CAR T-cell products under conditions of prolonged re-stimulation revealed a trend toward decreased cytotoxicity, as well as differences in proliferation dynamics and population composition between cell products obtained from B-ALL patients and healthy donors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nenasheva et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: